Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues

Journal of Medicinal Chemistry

Volumn 44, Issue 10, 2001, Pages 1594-1602

  Kim, D K ^a   Choi, W S ^a   Do Hyun Ryu, ^a   Ju Young Lee, ^a   Lee, N ^a   Kim, Y W ^a   Kim, J S ^a   Chang, K ^a   Im, G J ^a   Kim, T K ^a  

^a SK Chemicals   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 OXAZINE DERIVATIVE; 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 ETHYL 2,3 DIHYDRO 9 HYDROXY 1 ETHYL 12H 1,4 OXAZINO[3,2 F]PYRANO[3',4':6,7]INDOLIZINO[1,2 B]QUINOLINE 10,13(9H,15H) DIONE; 9 ETHYL 2,3 DIHYDRO 9 HYDROXY 1 METHYL 12H 1,4 OXAZINO[3,2 F]PYRANO[3',4':6,7]INDOLIZINO[1,2 B]QUINOLINE 10,13(9H,15H) DIONE; 9 ETHYL 2,3 DIHYDRO 9 HYDROXY 12H 1,4 OXAZINO[3,2 F]PYRANO[3',4':6,7]INDOLIZINO[1,2 B]QUINOLINE 10,13(9H,15H) DIONE; 9,16 DIETHYL 2,3 DIHYDRO 9 HYDROXY 12H 1,4 OXAZINO[3,2 F]PYRANO[3',4':6,7]INDOLIZINO[1,2 B]QUINOLINE 10,13(9H,15H) DIONE; ACETYLCHOLINESTERASE; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; EXATECAN; LURTOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHOLINESTERASE INHIBITORS; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035837063     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0004751     Document Type: Article

References (49)

1. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata
2. Treatment of malignant melanoma with camptothecin
3. Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer
4. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
5. Elevation of topoisomerase I. Messenger RNA protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
6. Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I
7. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
8. Action of camptothecin on mammalian cells in culture
9. Action of camptothecin and its derivatives on deoxyribonucleic acid
10. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese Hamster DC3F cells
11. DNA interactions of two clinical camptothecin drugs stabilize their active lactone forms
12. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
13. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin
14. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
15. 2 Recent advances in the medicinal chemistry and pharmacology of camptothecin
16. A review of the clinical experience with irinotecan (CPT-11)
17. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins
18. Topoisomerase I. Inhibitors: 1. Topotecan
19. Synthesis of water-soluble (Aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity
20. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic
21. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I
22. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies
23. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
24. 9-Aminocamptothecin and beyond. Preclinical and clinical studies
25. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins
26. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities
27. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues
28. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues
29. Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues
30. Synthesis and antitumor activity of camptothecin analogues
31. Chemical modification of an antitumor alkaloid camptothecin: Synthesis and antitumor activity 7-C-substituted camptothecins
32. An efficient conversion of camptothecin to 10-hydroxycamptothecin
33. 2-camptothecin based on a sequence of palladium-catalysed reductions
34. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues
35. Phase I study of weekly intravenous infusions of CPT-11 a new derivative of camptothecin in the treatment of advanced non-small-cell lung cancer
36. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
37. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
38. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
39. Preferential binding of the carboxylate form of camptothecin by human serum albumin
40. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability
41. Differential interactions of camptothecin lactone and carboxylate forms with human blood components
42. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study
43. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs
44. Efficacy of oral irinotecan against neuroblastoma xenografts
45. Evaluation of a tetrazole-based semiautomated calorimetric assay: Assessment of chemosensitivity testing
46. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay
47. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
48. A new and rapid colorimetric determination of acetylcholinesterase activity